Palisade Bio Reveals New Corporate Identity and Commitment
The company is focusing on its mission to be at the forefront of developing innovative therapies for immune, inflammatory, and fibrotic diseases.
Making Progress with Clinical Trials for PALI-2108
Palisade Bio, Inc. (NASDAQ: PALI) has made noteworthy strides in reshaping its corporate identity and has updated its website to better reflect its commitment to pioneering therapies for patients battling significant autoimmune and inflammatory conditions.
Dedicated to Stakeholders
CEO J.D. Finley expressed excitement about aligning the company's brand with its mission of delivering innovative product candidates to those in need. "As we move forward with our pipeline and accumulate critical data, it's vital that our branding embodies the vision we hold for our future. We believe next-generation precision therapies will play a crucial role in our efforts to address these diseases," he shared.
In-Depth Development for Ulcerative Colitis
The flagship program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug designed for treating moderate-to-severe ulcerative colitis (UC). This condition poses significant challenges, and Palisade intends to employ advanced machine learning techniques to improve treatment efficacy. By accurately identifying patients showing increased PDE4 activity and other vital markers of colitis through RNA sequencing, Palisade seeks to enhance responses to PDE4 inhibitors.
Expanding the Pipeline with Innovative Technologies
Palisade’s groundbreaking platform has the potential to broaden its reach into various therapeutic areas that tackle immune and fibrotic diseases. Additionally, the company is developing PALI-1908, which targets fibrostenotic Crohn’s Disease, aiming to create synergies with its main program.
Engaging Stakeholders with a Fresh Digital Presence
The launch of Palisade's new website now serves as an important resource for investors and stakeholders alike. The latest corporate presentation is available, shedding light on their current projects and strategic visions. Those interested in keeping up with the company’s progress can visit its revamped online platform at palisadebio.com.
About Palisade Bio
Palisade Bio is committed to discovering and developing cutting-edge therapeutics that address the needs of patients suffering from autoimmune and inflammatory diseases. Through targeted therapies, Palisade aims to transform treatment approaches and significantly enhance patient outcomes.
Frequently Asked Questions
What is the main focus of Palisade Bio?
Palisade Bio primarily focuses on developing innovative therapies for autoimmune and inflammatory diseases, addressing unmet medical needs with dedication.
What is the lead product candidate for Palisade Bio?
The lead product candidate, PALI-2108, is aimed at treating moderate ulcerative colitis with advanced therapeutic strategies.
How does Palisade Bio incorporate technology in its development?
Palisade Bio integrates machine learning and RNA sequencing techniques to improve patient identification and treatment outcomes significantly.
Where can I find more information about Palisade Bio?
You can check out the company’s website at palisadebio.com for further insights and updates on their work.
Who should I contact for investor relations?
For investor relations inquiries, you can connect with JTC Team, LLC. Specifically, reach out to Jenene Thomas at 833-475-8247 or via email at PALI@jtcir.com.
